Statin use and survival following glioblastoma multiforme

Cancer Epidemiology

Volumn 38, Issue 6, 2014, Pages 722-727

  Gaist, David ^a   Hallas, Jesper ^b   Friis, Søren ^c   Hansen, Steinbjørn ^a   Sørensen, Henrik Toft ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain tumour epidemiology; Cohort study; Glioblastoma multiforme; Glioma; Risk; Statins

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRESCRIPTION; SENSITIVITY ANALYSIS; SURVIVAL; BRAIN NEOPLASMS; MIDDLE AGED; MORTALITY;

AGED; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 84912089373     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.09.010     Document Type: Article

References (41)

1. Central Brain Tumor Registry of the United States (CBTRUS) Statistical report: primary brain tumors in the United States 2000-2004 2008, Central Brain Tumor Registry of the United States, Hinsdale, IL.
2. Bondy M.L., Scheurer M.E., Malmer B., Barnholtz-Sloan J.S., Davis F.G., Il'yasova D., et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113:1953-1968.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Dansk Neuro Onkologisk Gruppe Retningslinjer for behandling af intrakranielle gliomer hos voksne 2012, [In Danish]. http://www.dnog.dk/dokumenter.
5. Lamborn K.R., Chang S.M., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004, 6:227-235.
6. Stark A.M., van de Bergh J., Hedderich J., Mehdorn H.M., Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 2012, 114:840-845.
7. Weller M., Pfister S.M., Wick W., Hegi M.E., Reifenberger G., Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013, 14:e370-e379.
8. Gazzerro P., Proto M.C., Gangemi G., Malfitano A.M., Ciaglia E., Pisanti S., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012, 64:102-146.
9. Ahern T.P., Pedersen L., Tarp M., Cronin-Fenton D.P., Garne J.P., Silliman R.A., et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011, 103:1461-1468.
10. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
11. Ferris J.S., McCoy L., Neugut A.I., Wrensch M., Lai R. HMG CoA reductase inhibitors NSAIDs and risk of glioma. Int J Cancer 2012, 131:E1031-E1037.
12. Gaist D., Andersen L., Hallas J., Sørensen H.T., Schrøder H.D., Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer 2013, 108:715-720.
13. Gjerstorff M.L. The Danish cancer registry. Scand J Public Health 2011, 39(7 Suppl.):42-45.
14. Pedersen C.B. The Danish civil registration system. Scand J Public Health 2011, 39(Suppl. 7):22-25.
15. Kildemoes H.W., Toft Sørensen H., Hallas J. The Danish National Prescription registry. Scand J Public Health 2011, 39(7 Suppl.):38-41.
16. Lynge E., Sandegaard J.L., Rebolj M. The Danish national patient register. Scand J Public Health 2011, 39(Suppl. 7):30-33.
17. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2013. Oslo 2012.
18. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008, 168:329-335.
19. Kanstrup H., Lassen J.F., Heickendorff L., Lauritzen T., Larsen M.L. Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med 2004, 255:367-372.
20. Hartz I., Sakshaug S., Furu K., Engeland A., Eggen A.E., Njølstad I., et al. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol 2007, 7:14.
21. Tapia-Pérez J.H., Kirches E., Mawrin C., Firsching R., Schneider T. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 2011, 67:1193-1201.
22. Kitahara C.M., Linet M.S., Brenner A.V., Wang S.S., Melin B.S., Wang Z., et al. Personal history of diabetes, genetic susceptibility to diabetes, and risk of brain glioma: a pooled analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2014, 23:47-54.
23. Cahoon E.K., Inskip P.D., Gridley G., Brenner A.V. Immune-related conditions and subsequent risk of brain cancer in a cohort of 4.5 million male US veterans. Br J Cancer 2014, 110:1825-1833.
24. Carstensen B., Witte D.R., Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012, 55:948-958.
25. Chen C., Xu T., Chen J., Zhou J., Yan Y., Lu Y., et al. Allergy and risk of glioma: a meta-analysis. Eur J Neurol 2011, 18:387-395.
26. McCarthy B.J., Rankin K., Il'yasova D., Erdal S., Vick N., Ali-Osman F., et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev 2011, 20:370-378.
27. Scheurer M.E., Amirian E.S., Davlin S.L., Rice T., Wrensch M., Bondy M.L. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer 2011, 129:2290-2296.
28. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
29. Schmidt L.S., Nielsen H., Schmiedel S., Johansen C. Social inequality and incidence of and survival from tumours of the central nervous system in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008, 44:2050-2057.
30. Jensen V.M., Rasmussen A.W. Danish education registers. Scand J Public Health 2011, 39(7 Suppl.):91-94.
31. Glynn R.J., Schneeweiss S., Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253-259.
32. Rassen J.A., Shelat A.A., Myers J., Glynn R.J., Rothman K.J., Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012, 21(Suppl. 2):69-80.
33. Kildemoes H.W., Hendriksen C., Andersen M. Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemol Drug Saf 2012, 21:1027-1035.
34. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
35. Thomsen R.W., Johnsen S.P., Olesen A.V., Mortensen J.T., Bøggild H., Olsen J., et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005, 60:534-542.
36. Thomsen R.W., Nielsen R.B., Nørgaard M., Horsdal H.T., Stürmer T., Larsen F.B., et al. Lifestyle profile among statin users. Epidemiology 2013, 24:619-620.
37. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
38. Riahi S., Fonager K., Toft E., Hvilsted-Rasmussen L., Bendsen J., Paaske Johnsen S., et al. Use of lipid-lowering drugs in 1991-98 in Northern Jutland, Denmark. Br J Clin Pharmacol 2001, 52:307-311.
39. Larsen J., Andersen M., Kragstrup J., Gram L.F. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002, 53:375-378.
40. Glynn R.J., Knight E.L., Levin R., Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001, 12:682-689.
41. Benson V.S., Pirie K., Green J., Casabonne D., Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008, 99:185-190.